Novyra Pharmachem Limited , formerly known as Bansisons Tea Industries Limited, has submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The company also maintains its scheduled board meeting for April 18, 2026, to consider Q4FY26 and FY26 audited financial results.

Regulatory Compliance Certificate

On April 10, 2026, Novyra Pharmachem Limited filed the mandatory certificate with BSE Limited, confirming compliance with dematerialization requirements for Q4FY26. The certificate was signed by Director Anilkumar Mohanbhai Amreliya (DIN: 11339148) and submitted to BSE under scrip code 519353.

Registrar Confirmation

S.K. Infosolutions Pvt. Limited, the company's registrar and transfer agent, provided confirmation on April 04, 2026, regarding the dematerialization process. The registrar confirmed that securities received from depository participants during Q4FY26 were properly processed and that security certificates were mutilated and cancelled after due verification.

Upcoming Board Meeting

The company maintains its previously announced board meeting scheduled for April 18, 2026, at the registered office in Surat, Gujarat. The meeting will address audited financial results for Q4FY26 and FY26, along with the auditor's report pursuant to SEBI LODR Regulation 33.

Trading Window Status

In compliance with insider trading regulations, the trading window remains closed from April 01, 2026, and will reopen 48 hours after the declaration of financial results. This restriction applies to all designated persons under the company's Code of Fair Disclosure.

Company Information

Novyra Pharmachem Limited operates under CIN L21001GJ1987PLC171085 with its registered office at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Surat, Gujarat. The company maintains regulatory compliance through its registrar S.K. Infosolutions Pvt. Limited, located in Kolkata.

Bansisons Tea Industries Limited, now operating as Novyra Pharmachem Limited, conducted its independent directors meeting on March 20, 2026, at its registered office in Surat, Gujarat. The meeting was held in compliance with Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015, read with Schedule IV of the Companies Act, 2013.

Meeting Details and Duration

The independent directors meeting was conducted for the Financial Year 2025-26, commencing at 01.00 P.M. and concluding at 06.45 P.M. The extended duration reflects the comprehensive nature of the governance review undertaken by the independent directors.

Key Agenda Items Reviewed

The independent directors addressed three critical governance areas during their meeting. The comprehensive review process encompassed multiple aspects of board effectiveness and corporate governance standards.

The meeting agenda included:

• Review of performance of non-independent directors and the board of directors as a whole
• Assessment of the chairperson's performance, incorporating feedback from both executive and non-executive directors
• Evaluation of information flow quality, quantity, and timeliness between management and the board of directors

Regulatory Compliance and Corporate Governance

The meeting fulfills the company's statutory obligations under SEBI regulations, ensuring adherence to corporate governance standards. The independent directors' assessment of information flow between management and the board is particularly significant for ensuring effective board functioning.

Company Information

Novyra Pharmachem Limited operates from its registered office located at R S No 432, City Survey No 3763, Ground Floor, Pavthawala Compound, Vastadevadi Road, Surat, Gujarat. The company maintains its BSE listing under scrip code 519353 and continues to operate under CIN L21001GJ1987PLC171085.

The meeting outcome was communicated to BSE Limited as part of the company's disclosure obligations under Regulation 30 of SEBI LODR Regulations, ensuring transparency with stakeholders and regulatory authorities.